Company · BMY
Healthcare · 1 research article
Delayed up to 15 min · Source: Finnhub · Not investment advice
BMY trades at 9.3x P/E and a 4.5% yield while three forensic mispricings sit in plain sight: the Eliquis IRA cliff that didn't happen, a growth/legacy crossover already cleared in 2025, and a $14B Cobenfy option the Street is valuing at zero. Rating: BUY. 12-month target $78, multi-year intrinsic $95+.
| Company | View | Revenue YoY | EPS YoY | Guidance | Last report | |
|---|---|---|---|---|---|---|
| BMY Bristol-Myers Squibb | LONG | +7% | — | raised | Oct 29, 2026 | |
| CVS CVS Health | LONG | +7.3% | — | raised | Aug 5, 2026 | Compare |
| DHR Danaher | LONG | +8.5% | — | revised | Oct 21, 2026 | Compare |
| HUM Humana | LONG | — | — | — | — | Compare |
| ISRG Intuitive Surgical | LONG | +22% | — | issued | Oct 20, 2026 | Compare |
| LLY Eli Lilly | LONG | +39% | +7% | raised | Oct 29, 2026 | Compare |
| MRK Merck | LONG | — | — | issued | Oct 29, 2026 | Compare |
| PFE Pfizer | LONG | — | — | — | — | Compare |
Growth figures are year-over-year changes extracted automatically from each company's latest earnings release and can contain errors.
Widgets by TradingView. They load only when you click, so the page stays fast.
Forensic equity research on US stocks. No spam, unsubscribe anytime.
